Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (251-260 of 320) with videos related to

Pageof 32
Sort By:
Breast Cancer Research and Treatment|July 29, 2008
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancerRupert Bartsch, Brigitte Mlineritsch, Michael Gnant, et al.
Cancer Chemotherapy and Pharmacology|February 8, 2008
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancerRupert Bartsch, Catharina Wenzel, Simon P Gampenrieder, et al.
British Journal of Cancer|April 28, 2005
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancerW Schippinger, M Jagoditsch, C Sorré, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancerJ F R Robertson, G G Steger, P Neven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2018
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patientsA Matikas, T Foukakis, V Moebus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1993
Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipientsJ N Bavinck, L Gissmann, F H Claas, et al.
Breast Cancer Research and Treatment|December 18, 2007
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)Susanne Taucher, Guenther G Steger, Raimund Jakesz, et al.
Acta Oncologica (Stockholm, Sweden)|February 7, 2001
Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patientsH T Greinix, W Linkesch, M Seifert, et al.
British Journal of Cancer|October 11, 2012
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivorsA S Berghoff, Z Bago-Horvath, A Ilhan-Mutlu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2012
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancerRupert Bartsch, Zsuzsanna Bago-Horvath, Anna Berghoff, et al.
Pageof 32

Showing results (251-260 of 320) with videos related to

Sort By:
Pageof 32
Breast Cancer Research and Treatment|July 29, 2008
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancerRupert Bartsch, Brigitte Mlineritsch, Michael Gnant, et al.
Cancer Chemotherapy and Pharmacology|February 8, 2008
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancerRupert Bartsch, Catharina Wenzel, Simon P Gampenrieder, et al.
British Journal of Cancer|April 28, 2005
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancerW Schippinger, M Jagoditsch, C Sorré, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Activity of fulvestrant in HER2-overexpressing advanced breast cancerJ F R Robertson, G G Steger, P Neven, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2018
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patientsA Matikas, T Foukakis, V Moebus, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1993
Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipientsJ N Bavinck, L Gissmann, F H Claas, et al.
Breast Cancer Research and Treatment|December 18, 2007
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)Susanne Taucher, Guenther G Steger, Raimund Jakesz, et al.
Acta Oncologica (Stockholm, Sweden)|February 7, 2001
Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patientsH T Greinix, W Linkesch, M Seifert, et al.
British Journal of Cancer|October 11, 2012
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivorsA S Berghoff, Z Bago-Horvath, A Ilhan-Mutlu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2012
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancerRupert Bartsch, Zsuzsanna Bago-Horvath, Anna Berghoff, et al.
Pageof 32